1Siragy H. Angiotensin II receptor blockers: review of the binding characteristics. Am J Cardiol, 1999, 84: 3S-8S.
2Neutel JM, Smith DHG. Dose response ane antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther, 1998, 15: 206-217.
3Myers MG. Suggested guidelines for determining the trough-to-peak ratio of antihypertensive drugs. Am J Hypertens, 1996, 9: 76S-82S.
4Mallion JM, Siche JP, Lacourciere Y, et al. ABPM comparison of antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens, 1999, 13: 657-664.
5Lipicky RJ. Trough/peak ratio: the rationale behind the United States Food and Drug Administration reco mmendations. J Hypertens, 1994, 12(Suppl 8): S17-S19.
6Zannad F, Matzinger A, Larche J. Trough/peak ratios of once-daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens, 1996, 9: 633-643.
7Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death. Circulation, 1987, 75: 131-138.
